Table 2.
Kidneys—histopathology observations.
| Males (5 per group) | Females (5 per group) | |||||
|---|---|---|---|---|---|---|
| CRM | J8-K4S2 | p*17-K4S2 | CRM | J8-K4S2 | p*17-K4S2 | |
| Day 57 | ||||||
| Within normal limits | 2 | 3 | 4 | 5 | 4 | 3 |
| Chronic progressive nephropathy, minimal | 3 | 2 | 0 | 0 | 1 | 0 |
| Dilation; tubular, minimal | 0 | 0 | 1 | 0 | 0 | 1 |
| Atrophy; tubular, minimal | 0 | 0 | 1 | 0 | 0 | 0 |
| Infiltration; mixed, minimal | 0 | 0 | 0 | 0 | 0 | 1 |
| Day 86 | ||||||
| Within normal limits | 2 | 1 | 4 | 3 | 4 | 2 |
| Cast | 1 | 1 | 0 | 1 | 0 | 1 |
| Chronic progressive nephropathy, minimal | 0 | 1 | 1 | 0 | 1 | 1 |
| Chronic progressive nephropathy, mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Cyst; tubular | 1 | 1 | 0 | 0 | 0 | 0 |
| Dilation; pelvic, mild | 1 | 0 | 0 | 0 | 0 | 0 |
| Infiltration, lymphocytic; interstitial | 0 | 1 | 0 | 1 | 0 | 1 |
| Hypertrophy; tubular, minimal | 0 | 0 | 0 | 0 | 0 | 1 |
CRM, CRM/Alum; J8-K4S2, J8-CRM + K4S2-CRM/Alum; p*17-K4S2; p*17-CRM + K4S2-CRM/Alum.